Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 25,50 € (+14,35 %). La mediana es de 24,49 € (+9,82 %).
| Comprar |
8 |
| Mantener |
11 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Envista rises premarket after JPMorgan upgrade and price-target increase
Envista shares rose about 2.3% premarket after JPMorgan upgraded the stock from “Neutral” to “Overweight” and raised the price target from $29 to $32. The bank cited improved operational execution and a valuation that lags recent fundamentals, and expects to set a mid‑term growth target slightly above the previous 2–4% range at the investor day on Sept. 17. Envista had already reported Q2 results that beat expectations on adjusted EPS and revenue and subsequently raised its full‑year forecast. » Más en de.investing.com
Envista Holdings: CEO Paul Keel named chair of the board; executives receive special compensation
Envista Holdings named President and CEO Paul Keel effective immediately as chair of the board; Scott Huennekens remains lead independent director. The board approved a salary increase for Keel from $1.1 million to $1.3 million and a one-time equity award worth $10 million ($5 million RSUs, $5 million PSUs with a four-year vesting period). CFO Eric Hammes received PSUs worth $1.5 million with the same performance conditions. The actions are based on an SEC filing; Envista recently reported Q2 results and revenue above expectations and raised its full-year outlook. » Más en de.investing.com
Envista raises 2026 outlook after Q2 sales, margin and EPS beat
Envista reported Q2 sales of $731 million, driven by 5% core revenue growth, with adjusted EBITDA up 28% and adjusted EPS of $0.41 (up 58%). Free cash flow was $105 million and the company repurchased about 2.4 million shares. Equipment and consumables led segment growth while Specialty Products saw strength from Spark clear aligners and implant investments. Management raised 2026 guidance to 3.5–4.5% core sales growth, 11–14% adjusted EBITDA growth and adjusted EPS of $1.50–$1.55, but warned China volume-based procurement could pressure pricing in H2. » Más en finance.yahoo.com
Envista Holdings announces $300 million share buyback program and confirms outlook
Envista Holdings reports Q1 revenue growth (+14.4% nominal; organic +9.5% before special items), adjusted EBITDA of $98.9 million (+25%) and adjusted earnings per share of $0.36. Operating cash flow and free cash flow were negative, driven by higher investments in plants in China and Finland. Management confirms the full-year outlook (organic growth 2–4%, adjusted EBITDA +7–13%) and launches a new $300 million repurchase program through the end of 2029. The stock is likely to trade sideways in the short term; the next price catalysts are expected from the quarterly results on August 5. » Más en finanzen.net
Envista Holdings named a top Ariel Investments pick after strong Q1 momentum
Ariel Investments lists Envista Holdings as a top stock to buy following a strong first quarter marked by 9.5% core revenue growth, 25% adjusted EBITDA growth and 50% EPS growth. Barclays reiterated an Overweight rating but trimmed its price target to $32 from $34. Envista reiterated full-year guidance with sales growth of 2–4%, adjusted EBITDA growth of 7–13% and adjusted diluted EPS guidance of $1.35–$1.45. » Más en finance.yahoo.com
Datos financieros de la empresa
| (EUR) | octubre de 2026 | YoY |
|---|---|---|
| Ingresos | 614,16 M | 7,29 % |
| Beneficio bruto | 355,79 M | 11,00 % |
| Beneficio neto | 451,45 M | 1843,59 % |
| EBITDA | 473,74 M | 529,28 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 3578,24 M € |
Número de acciones | 160,35 M |
Máximo/mínimo de 52 semanas | 27,60 € - 17,03 € |
| Dividendos | No |
Beta | 0,94 |
Ratio P/E | 6,26 |
Ratio PEG | 0,00 |
Ratio P/B | 1,28 |
Ratio P/S | 1,37 |
Perfil de la empresa
Envista Holdings Corporation, junto con sus filiales, se dedica al desarrollo, la venta y la comercialización de productos dentales en Estados Unidos, China y en el resto del mundo. La compañía opera en dos segmentos, Specialty Products & Technologies y Equipment & Consumables. El segmento Specialty Products & Technologies de la compañía ofrece sistemas de implantes dentales, sistemas de cirugía guiada, biomateriales y prótesis prefabricadas y personalizadas para cirujanos orales, prostodoncistas y periodoncistas, bajo las marcas Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera y Orascoptic; así como brackets y alambres, tubos y bandas, arcos de alambre, alineadores transparentes, tratamientos ortodónticos digitales, retenedores y otros productos de laboratorio de ortodoncia, bajo las marcas Damon, Insignia, AOA y Spark. Este segmento también ofrece paquetes de software, que incluyen DTX Studio Implant para la planificación de tratamientos de implantes dentales; TX Studio Lab para la planificación de tratamientos protésicos; y DTX Studio Clinic para almacenar y acceder a diversas imágenes clínicas de pacientes. El segmento Equipment & Consumables de la compañía ofrece equipos y suministros dentales, incluidos sistemas de imagen digital, sensores, software y otros sistemas de visualización y magnificación; sistemas endodónticos y consumibles relacionados; materiales restauradores, fresas rotatorias, materiales de impresión, agentes adhesivos y cementos; y productos para la prevención de infecciones. Este segmento ofrece sus productos bajo las marcas Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo y CaviWipes a consultorios dentales, clínicas y hospitales. Envista Holdings Corporation se constituyó en 2018 y tiene su sede central en Brea, California.
| Nombre | Envista Holdings |
| CEO | Paul A. Keel |
| Sede | Brea,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 18/09/2019 |
| Empleados | 12.000 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
XETRA | 0HV.DE |
NYSE | NVST |
Düsseldorf | 0HV.DU |
Frankfurt | 0HV.F |
München | 0HV.MU |
Toronto Stock Exchange | CLZ.V |
Pnk | ICRD |